Fragmento

Article commented: Yong KJ, Gao C, Lim JS, Yan B, Yang H, Dimitrov T, Kawasaki A, et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 2013; 368: 2266-76. Comment: Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer worldwide and the third most frequent cause of cancer-related death, with increasing incidence in traditionally low-frequency regions like the United States and Northern Europe. A relevant proportion of patients with HCC present with advanced disease, and the only approved therapy in this subgroup is the multi-kinase inhibitor sorafenib, approved in 2008.The lack of novel and/or second-line therapies, and the limited survival benefit provided by sorafenib underscore the urgent need for novel treatment options in advanced HCC. This goal may be more easily achieved with a better understanding of the molecular pathogenesis of this cancer, which is characterized by a marked heterogeneity. Unfortunately, the molecular mechanisms leading to HCC diversity and to its variable prognosis are still far to be defined.

Palabras clave:

2014-02-28   |   375 visitas   |   Evalua este artículo 0 valoraciones

Vol. 13 Núm.2. Marzo-Abril 2014 Pags. 305-307 Ann Hepatol 2014; 13(2)